FIELD OF INVENTION
[001] The present disclosure broadly relates to field of pain-relief compositions and particularly relates to a herbal composition comprising Angelica sinensis extract and Thymus vulgaris extract.
BACKGROUND OF INVENTION
[002] Many girls and women suffer from abdominal cramps and other discomforts during menses. Primary dysmenorrhoea is the term used when the pain is caused due to contraction of uterine smooth muscle cells. It has been reported that 10 out of 100 women experience an increased amount of pain due to which they are unable to carry out their daily chores for one to three days every month. Therefore, it is pertinent to investigate possible options that can be used to get relief from the pain. Contractions in uterine smooth muscles, mediated by prostaglandins PGF-2a, is reported to be responsible for cramps and pain associated with menses (Powell et al., Prostaglandins, 1985, 29(2): 273-90; Lumsden et al., Br. J Obstet Gynaecol, 1983, 90(12): 1135-40). [003] During menstrual period, influence of the perception of pain and tightening of muscles in the womb to shed the lining of the womb is caused by prostaglandins. There are drugs available in the market that help in relieving pain during these times. The drugs mainly belong to a class of non-steroidal anti-inflammatory drugs (NSAIDS). NSAIDS are able to lessen the pain by reducing the levels of prostaglandins. While NSAIDs are available to provide relief, their effect is temporary and reported to cause many side effects (Hsu et al., Phytomedicine, 2006, vol. 13, issues 1-2, 94-100). One of the known side-effects include stomach related problems associated with NSAIDS. The side-effects include serious problems like thrombosis which can be life threatening.
[004] EP2789345A1 discloses a new composition, preferably with delayed release, containing N-acetyl cysteine, alpha-lipoic acid, and bromelain, in addition to the use thereof in the treatment of endometriosis, dysmenorrhoea, and/or pelvic pain.

[005] CA1300509C discloses pharmaceutical composition for relieving symptoms of dysmenorrhea and/or premenstrual syndrome comprising a combination of acetylsalicylic acid or ibuprofen and the diuretic pamabrom, optionally it may also contain an antihistamine.
[006] In spite of availability of various pain-relief compositions, there is still a dearth in terms of effective and safe composition.
SUMMARY OF THE INVENTION
[007] In an aspect of the present invention, there is provided a composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition.
[008] In an aspect of the present invention, there is provided a process for preparing the composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, said process comprising: (i) obtaining Angelica sinensis extract; (ii) obtaining Thymus vulgaris extract; and (iii) contacting the Angelica sinensis extract with the Thymus vulgaris extract, to obtain the composition.
[009] These and other features, aspects, and advantages of the present subject matter will be better understood with reference to the following description and appended claims. This summary is provided to introduce a selection of concepts in a simplified form. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter.
BRIEF DESCRIPTION OF ACCOMPANYING DRAWINGS
[0010] The following drawings form a part of the present specification and are included to further illustrate aspects of the present disclosure. The disclosure may be better understood by reference to the drawings in combination with the detailed description of the specific embodiments presented herein.

[0011] Figure 1 illustrates inhibitory effect of different compositions on PGF-2a production, in accordance with an embodiment of the present disclosure.
DETAILED DESCRIPTION OF THE INVENTION
[0012] Those skilled in the art will be aware that the present disclosure is subject to
variations and modifications other than those specifically described. It is to be
understood that the present disclosure includes all such variations and
modifications. The disclosure also includes all such steps, features, compositions,
and compounds referred to or indicated in this specification, individually or
collectively, and any and all combinations of any or more of such steps or features.
Definitions
[0013] For convenience, before further description of the present disclosure,
certain terms employed in the specification, and examples are delineated here.
These definitions should be read in the light of the remainder of the disclosure and
understood as by a person of skill in the art. The terms used herein have the
meanings recognized and known to those of skill in the art, however, for
convenience and completeness, particular terms and their meanings are set forth
below.
[0014] The articles "a", "an" and "the" are used to refer to one or to more than one
(i.e., to at least one) of the grammatical object of the article.
[0015] The terms "comprise" and "comprising" are used in the inclusive, open
sense, meaning that additional elements may be included. It is not intended to be
construed as "consists of only".
[0016] Throughout this specification, unless the context requires otherwise the
word "comprise", and variations such as "comprises" and "comprising", will be
understood to imply the inclusion of a stated element or step or group of element or
steps but not the exclusion of any other element or step or group of element or
steps.
[0017] The term "including" is used to mean "including but not limited to".
"Including" and "including but not limited to" are used interchangeably.

[0018] Carriers are substances that serve as mechanisms to improve the delivery and the effectiveness of the drug.
[0019] A diluent (also referred to as filler, dilutant, or thinner) is a diluting agent. [0020] An excipient is an inactive substance that serves as a vehicle or medium for a drug or other active substance. Excipients include colouring agents, humectants, preservatives, emollients, and combinations thereof.
[0021] Ratios, concentrations, amounts, and other numerical data may be presented herein in a range format. It is to be understood that such range format is used merely for convenience and brevity and should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. For example, a w/w ratio range of about 1:1.25 to about 1:3 should be interpreted to include not only the explicitly recited limits of about 1:1.25 to about 1:3, but also to include sub-ranges, such as 1:1.3 to 1:2.25, 1:2.1 to 1:2.5, and so forth, as well as individual amounts, including fractional amounts, within the specified ranges, such as 1:2, 1:2.5, for example.
[0022] To address the problems discussed previously, the present disclosure discloses a combination of Angelica sinensis extract and Thymus vulgaris extract, wherein the combination is able to reduce production of PGF-2a, thereby reducing dysmenorrhea. A. sinensis extract is known in Chinese traditional medicine to help relieve menstrual pain by vasodilation. T. vulgaris essential oil has also been shown to relieve dysmenorrhoea. However, the present disclosure discloses the synergistic effect of a specific combination of A. sinensis extract and T. vulgaris extract in reduction of PGF-2a, demonstrating the enhanced potential of this combination in alleviating menstrual pain.
[0023] The present disclosure discloses a composition comprising (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition and the Thymus vulgaris extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition. The weight ratio of A sinensis

extract to T. vulgaris extract is in a range of 1:1.25 to 1:3. In an alternate aspect of the present disclosure, weight ratio of A. sinensis extract to T. vulgaris extract is in a range of 1:0.25 to 1:0.75.
[0024] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the disclosure, the preferred methods, and materials are now described. All publications mentioned herein are incorporated herein by reference. [0025] The present disclosure is not to be limited in scope by the specific embodiments described herein, which are intended for the purposes of exemplification only. Functionally-equivalent products, compositions, and methods are clearly within the scope of the disclosure, as described herein. [0026] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition. In another embodiment of the present disclosure, the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.06% with respect to the composition.
[0027] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020% - 0.1% with respect to the composition. [0028] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.06% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020% - 0.06% with respect to the composition. [0029] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein

the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, and wherein the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.25 to 1:3. In another embodiment of the present disclosure, the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.06% with respect to the composition, and the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.75 to 1:2.5.
[0030] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020% - 0.1% with respect to the composition, and wherein the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.25 to 1:3. In another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.75 to 1:2.50. In yet another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.90 to 1:2.10.
[0031] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020% - 0.1% with respect to the composition, and wherein the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.25 to 1:3. In another embodiment of the present disclosure, the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.06% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020% - 0.06% with respect to the composition. [0032] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.06%

with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020% - 0.06% with respect to the composition, and wherein the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.75 to 1:2.5.
[0033] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020% - 0.1% with respect to the composition, and wherein the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is 1:2.
[0034] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage of 0.025%) with respect to the composition, and the Thymus vulgaris extract has a weight percentage of 0.05% with respect to the composition, and wherein the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is 1:2.
[0035] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, and wherein the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.25 to 1:0.75. In another embodiment of the present disclosure, the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.06%> with respect to the composition, and wherein the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.4 to 1:0.6.
[0036] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020% - 0.1% with respect to the composition, and

wherein the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.25 to 1:0.75. In another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.30 to 1:0.70. In yet another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.40 to 1:0.60.
[0037] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020% - 0.1% with respect to the composition, and wherein the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.25 to 1:0.75. In another embodiment of the present disclosure, the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.06% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020% - 0.06% with respect to the composition. [0038] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.06% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020% - 0.06% with respect to the composition, and wherein the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.40 to 1:0.60.
[0039] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020% - 0.1% with respect to the composition, and wherein the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is 1:0.5.

[0040] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage of 0.05% with respect to the composition, and the Thymus vulgaris extract has a weight percentage of 0.025% -0.1% with respect to the composition, and wherein the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is 1:0.5.
[0041] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; (b) Thymus vulgaris extract; (c) at least one carrier; (d) at least one diluent; and (e) at least one excipient, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 -0.1% with respect to the composition.
[0042] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; (b) Thymus vulgaris extract; (c) at least one carrier; (d) at least one diluent; and (e) at least one excipient, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 -0.1% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition. [0043] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; (b) Thymus vulgaris extract; (c) at least one carrier; (d) at least one diluent; and (e) at least one excipient, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 -0.1% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, and the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.25 to 1:3. In another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.75 to 1:2.50. In yet another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.90 to 1:2.10. [0044] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; (b) Thymus vulgaris extract; (c) at least one carrier; (d) at least one diluent; and (e) at least one excipient, wherein the

Angelica sinensis extract has a weight percentage in the range of 0.020 -0.1% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, and the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is 1:2. In another embodiment of the present disclosure, the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.06% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020 -0.06%) with respect to the composition.
[0045] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; (b) Thymus vulgaris extract; (c) at least one carrier; (d) at least one diluent; and (e) at least one excipient, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.06% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020 - 0.06%> with respect to the composition, and the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.25 to 1:3. In another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.75 to 1:2.50. In yet another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.90 to 1:2.10. [0046] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; (b) Thymus vulgaris extract; (c) at least one carrier; (d) at least one diluent; and (e) at least one excipient, wherein the Angelica sinensis extract has a weight percentage in the range of 0.025% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.05% with respect to the composition, and the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is 1:2. [0047] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; (b) Thymus vulgaris extract; (c) at least one carrier; (d) at least one diluent; and (e) at least one excipient, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 -0.1% with respect to the composition, and the Thymus vulgaris extract has a weight

percentage in the range of 0.020 - 0.1% with respect to the composition, and the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.25 to 1:0.75. In another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.30 to 1:0.70. In yet another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.40 to 1:0.60. [0048] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; (b) Thymus vulgaris extract; (c) at least one carrier; (d) at least one diluent; and (e) at least one excipient, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, and the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is 1:0.5. In another embodiment of the present disclosure, the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.06% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020 -0.06%) with respect to the composition.
[0049] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; (b) Thymus vulgaris extract; (c) at least one carrier; (d) at least one diluent; and (e) at least one excipient, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.06% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020 - 0.06%> with respect to the composition, and the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.25 to 1:0.75. In another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.30 to 1:0.70. In yet another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.40 to 1:0.60. [0050] In an embodiment of the present disclosure, there is provided a composition comprising: (a) Angelica sinensis extract; (b) Thymus vulgaris extract; (c) at least one carrier; (d) at least one diluent; and (e) at least one excipient, wherein the

Angelica sinensis extract has a weight percentage in the range of 0.050% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.025% with respect to the composition, and the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is 1:0.5. [0051] In an embodiment of the present disclosure, there is provided a process for preparing the composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, said process comprising: (i) obtaining Angelica sinensis extract; (ii) obtaining Thymus vulgaris extract; and (iii) contacting the Angelica sinensis extract with the Thymus vulgaris extract, to obtain the composition. In another embodiment of the present disclosure, the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.06%) with respect to the composition.
[0052] In an embodiment of the present disclosure, there is provided a process for preparing the composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1%> with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, said process comprising: (i) obtaining Angelica sinensis extract; (ii) obtaining Thymus vulgaris extract; and (iii) contacting the Angelica sinensis extract with the Thymus vulgaris extract, to obtain the composition. [0053] In an embodiment of the present disclosure, there is provided a process for preparing the composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1%> with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, said process comprising: (i) obtaining Angelica sinensis extract; (ii) obtaining Thymus vulgaris extract; and (iii) contacting the Angelica sinensis extract with the Thymus vulgaris extract, to obtain the composition, and the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.25 to 1:3. In another embodiment of the present disclosure, the

Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.75 to 1:2.25. In yet another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.90 to 1:2.10.
[0054] In an embodiment of the present disclosure, there is provided a process for preparing the composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.060% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020 - 0..060% with respect to the composition, said process comprising: (i) obtaining Angelica sinensis extract; (ii) obtaining Thymus vulgaris extract; and (iii) contacting the Angelica sinensis extract with the Thymus vulgaris extract, to obtain the composition, and the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.25 to 1:3. In another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.75 to 1:2.25. In yet another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.90 to 1:2.10.
[0055] In an embodiment of the present disclosure, there is provided a process for preparing the composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, said process comprising: (i) obtaining Angelica sinensis extract; (ii) obtaining Thymus vulgaris extract; and (iii) contacting the Angelica sinensis extract with the Thymus vulgaris extract, to obtain the composition, and the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.25 to 1:0.75. In another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.30 to 1:0.70. In yet another embodiment of the present disclosure, the Angelica

sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.40 to 1:0.60.
[0056] In an embodiment of the present disclosure, there is provided a process for preparing the composition comprising: (a) Angelica sinensis extract; and (b) Thymus vulgaris extract, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.06% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020 - 0.06% with respect to the composition, said process comprising: (i) obtaining Angelica sinensis extract; (ii) obtaining Thymus vulgaris extract; and (iii) contacting the Angelica sinensis extract with the Thymus vulgaris extract, to obtain the composition, and the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.25 to 1:0.75. In another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.30 to 1:0.70. In yet another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.40 to 1:0.60.
[0057] In an embodiment of the present disclosure, there is provided a process for preparing the composition comprising: (a) Angelica sinensis extract; (b) Thymus vulgaris extract; (c) at least one carrier; (d) at least one diluent; and (e) at least one excipient, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, said process comprising: (i) obtaining Angelica sinensis extract; (ii) obtaining Thymus vulgaris extract; (iii) obtaining the at least one carrier, the at least one diluent, and the at least one excipient, and contacting the Angelica sinensis extract, the Thymus vulgaris extract, the at least one carrier, the at least one diluent, and the at least one excipient, to obtain the composition. In another embodiment of the present disclosure, the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.06% with respect to the composition.
[0058] In an embodiment of the present disclosure, there is provided a process for preparing the composition comprising: (a) Angelica sinensis extract; (b) Thymus vulgaris extract; (c) at least one carrier; (d) at least one diluent; and (e) at least one

excipient, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, said process comprising: (i) obtaining Angelica sinensis extract; (ii) obtaining Thymus vulgaris extract; (iii) obtaining the at least one carrier, the at least one diluent, and the at least one excipient, and contacting the Angelica sinensis extract, the Thymus vulgaris extract, the at least one carrier, the at least one diluent, and the at least one excipient, to obtain the composition. In another embodiment of the present disclosure, the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.06% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020 - 0.06% with respect to the composition.
[0059] In an embodiment of the present disclosure, there is provided a process for preparing the composition comprising: (a) Angelica sinensis extract; (b) Thymus vulgaris extract; (c) at least one carrier; (d) at least one diluent; and (e) at least one excipient, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, said process comprising: (i) obtaining Angelica sinensis extract; (ii) obtaining Thymus vulgaris extract; (iii) obtaining the at least one carrier, the at least one diluent, and the at least one excipient, and contacting the Angelica sinensis extract, the Thymus vulgaris extract, the at least one carrier, the at least one diluent, and the at least one excipient, to obtain the composition, and wherein the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.25 to 1:3. In another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.75 to 1:2.50. In yet another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.90 to 1:2.10. [0060] In an embodiment of the present disclosure, there is provided a process for preparing the composition comprising: (a) Angelica sinensis extract; (b) Thymus vulgaris extract; (c) at least one carrier; (d) at least one diluent; and (e) at

least one excipient, wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, and the Thymus vulgaris extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition, said process comprising: (i) obtaining Angelica sinensis extract; (ii) obtaining Thymus vulgaris extract; (iii) obtaining the at least one carrier, the at least one diluent, and the at least one excipient, and contacting the Angelica sinensis extract, the Thymus vulgaris extract, the at least one carrier, the at least one diluent, and the at least one excipient, to obtain the composition, and wherein the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.25 to 1:0.75. In another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.30 to 1:0.70. In yet another embodiment of the present disclosure, the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.40 to 1:0.60.
[0061] In an embodiment of the present disclosure, there is provided a composition as described herein, wherein the Angelica sinensis extract comprises lingustilides having a weight percentage in the range of 0.5% to 1.5% with respect to the extract. In another embodiment of the present disclosure, the Angelica sinensis extract comprises lingustilides having a weight percentage in the range of 0.8% to 1.2% with respect to the extract.
[0062] In an embodiment of the present disclosure, there is provided a composition as described herein, wherein the Thymus vulgaris extract comprises thymol having a weight percentage in the range of 0.06% to 0.6% with respect to the extract. In another embodiment of the present disclosure, the Thymus vulgaris extract comprises thymol having a weight percentage in the range of 0.2% to 0.4% with respect to the extract.
[0063] In an embodiment of the present disclosure, there is provided a composition as described herein, wherein the composition inhibits prostaglandin PGF-2a production.
[0064] In an embodiment of the present disclosure, there is provided a composition as described herein, wherein the composition is used as a food supplement.

[0065] In an embodiment of the present disclosure, there is provided a composition
as described herein, wherein the composition is in form of a bar.
[0066] In an embodiment of the present disclosure, there is provided a composition
as described herein, wherein the composition is in a powder form.
[0067] In an embodiment of the present disclosure, there is provided a composition
as described herein, wherein the composition is in a liquid formulation.
[0068] In an embodiment of the present disclosure, there is provided a composition
as described herein, wherein the composition is in form of beverages. In another
embodiment of the present disclosure, the composition can be added to tea, and
juices.
[0069] In an embodiment of the present disclosure, there is provided a composition
as described herein, wherein the composition is used for pain relief during
dysmenorrhea.
[0070] Although the subject matter has been described in considerable detail with
reference to certain examples and implementations thereof, other implementations
are possible.
EXAMPLES
[0071] The disclosure will now be illustrated with working examples, which is
intended to illustrate the working of disclosure and not intended to take
restrictively to imply any limitations on the scope of the present disclosure. Unless
defined otherwise, all technical and scientific terms used herein have the same
meaning as commonly understood to one of ordinary skill in the art to which this
disclosure belongs. Although methods and materials similar or equivalent to those
described herein can be used in the practice of the disclosed methods and
compositions, the exemplary methods, devices and materials are described herein.
It is to be understood that this disclosure is not limited to particular methods, and
experimental conditions described, as such methods and conditions may apply.
[0072] The examples describe the synergistic effect of the composition as
disclosed in the present disclosure. The non-working examples assert the
importance of weight percentages and weight ratios to arrive at the synergistic
herbal composition as disclosed in the present disclosure.

Material and Methods
[0073] Angelica sinensis extract - Aqueous extract of A. sinensis was procured from Prakruti herbals ltd. Ten percent stock solution of the extract was prepared using DMEM medium (without FBS).
[0074] Thymus vulgaris extract - Aqueous extract of T. vulgaris was procured from Prakruti herbals ltd. Ten percent stock solution of the extract was prepared using DMEM medium (without FBS).
[0075] Studies involving RAW cells: RAW cells are murine macrophage cell line which are known to release prostaglandins in response to inflammatory stimulators like LPS. Cells were cultured in DMEM medium with FBS. Confluent cells (~ 1 x 105 cells) were treated with 100 ng/mL LPS for 24 hours at 37 ° C with 5 % C02. Post LPS stimulation, cells were either treated with herbal extracts in different combinations, or left untreated. For positive control LPS-stimulated cells were also treated with indomethacin which is a known NSAID. After 24 hours of further incubation, supernatant was collected for estimating the concentration of PGF-2a released by the cells. Supernatant was stored in - 20 ° C until further analysis. All the treatments were done with cells in DMEM medium supplemented with FBS. [0076] PGF-2a estimation: PGF-2a was estimated from the cell supernatants using Enzo PGF-2a ELISA kit (Cat No. ADI-900-069), as per the instruction manual. The kit uses an ELISA based method to detect PGF-2a concentration in samples. Supernatants were used for analysis after brief centrifugation at 1000 g for 5 minutes to get rid of debris. Absorbance of the reaction was measured at 405 nm and analysis was performed after blanking. Four parameter logistic curve fitting was performed using Multiskan software and concentrations of PGF-2a were estimated in different samples. Samples treated with extracts were compared to untreated samples by calculating the % inhibition in PGF-2a production. PGF-2a concentration in LPS-stimulated cells that were not treated with any extracts was considered as 0 % inhibition. Percent inhibition was calculated as follows:

Where, T = PGF-2a concentration in extract treated "LPS - stimulated" cells U = PGF-2a concentration in untreated "LPS - stimulated" cells
Working and Non-Working Examples
[0077] Compositions comprising A. sinensis extract and T. vulgaris extract were tested on RAW cells and the levels of PGF-2a were estimated as per the protocols mentioned in the previous section. The different combinations that were used for testing is mentioned in Table 1:
[0078] The table depicts the effect of each and every composition on inhibition of PGF-2a levels and Figure 1 is a graphical representation of the table. Indomethacin is a known pain-relief component and used as a positive control. Examples 1 to 6

depict the effect of individual extracts on PGF-2a levels. It can be appreciated from Table 1 that 0.025% of A. sinensis extract and 0.025% of T. vulgaris extract are not able to inhibit the levels of PGF-2a when tested individually. The other tested concentrations of A. sinensis extract shows 4% inhibition at 0.05%, and 49.2% inhibition at 0.1%. Similarly, 0.05% of T. vulgaris extract shows 37.3% inhibition and 0.1% of T. vulgaris displays 27% inhibition.
[0079] Further, analyzing the results of combinations of two extracts, it can be observed that Example 7 depicting a combination of 0.05% of both the extracts shows only 21.4% inhibition which is lesser than the individual value of T. vulgaris as depicted in Example 5. Also, Example 8 which depicts a combination of 0.025%) of both the extracts does not result in inhibition of PGF-2a. Thus, it is prudent to consider Examples 7 and 8 as non-working with respect to the inhibition ability. [0080] Surprisingly, on analyzing Example 9, it can be observed that a combination of A. sinensis extract 0.025% + T. vulgaris extract 0.05% (weight ratio 1:2) displays 51.5% inhibition of PGF-2a. The inhibition displayed by the present example is much higher than the additive inhibition percentages of 0.025%) of A. sinensis extract and 0.05% of T. vulgaris independently. The inhibition percentage displayed by Example 9 is even higher than the percentage inhibition displayed either by 0.1% A. sinensis extract or by 0.1% T. vulgaris extract. Thus, Example 9 displays higher inhibitory effects at a lower combined weight percentage of both the extracts as opposed to higher weight percentages of individual extracts. Therefore, Example 9 displays a synergistic effect in inhibiting PGF-2a, hence is a working example of the present composition.
[0081] Similarly, on analyzing Example 10, it can be observed that a combination of A. sinensis extract 0.05% + T. vulgaris extract 0.025% (weight ratio 1:0.5) displays around 27% inhibition of PGF-2a. The inhibition displayed by the present example is much higher than the additive inhibition percentages of 0.05% of A. sinensis extract and 0.025% of T. vulgaris independently. Thus, the present example is showing a synergistic effect and is a working example of the present composition.

[0082] On observing all the working and non-working examples presented in the disclosure, it can be appreciated that a combination of A. sinensis extract and T. vulgaris extract in a 1:1 weight ratio (Example 7 and 8) is not able to display synergistic effect in inhibiting PGF-2a, but on the other hand a combination of A. sinensis extract and T. vulgaris extract in a weight ratio of 1:2 (Example 9) and 1:0.5 (Example 10) are able to display synergistic effect.
[0083] Overall, it can be appreciated that considerable experimentation has assisted to arrive at a combination of both the extracts which display synergistic inhibition of PGF-2a only at specific weight ratios and specific weight percentages. Advantages of the present disclosure
[0084] The present disclosure discloses a composition comprising A. sinensis extract and T. vulgaris extract in specific weight ratios. The composition as disclosed synergistically inhibits production of PGF-2a prostaglandins, thus providing relief from pains arising during menstruation. One significant advantage of the present disclosure arises from the fact that both the active used in preparing the composition are herbal in nature thus can be contemplated to have negligible side effects upon prolonged usage. The wide availability of both the extracts and the ease of preparation of the composition can be considered as additional benefits of the present disclosure. The composition can be used as an additional ingredient in regular food supplements to help in pain relief.

I/We Claim:
1. A composition comprising:
a) Angelica sinensis extract; and
b) Thymus vulgaris extract,
wherein the Angelica sinensis extract has a weight percentage in the range of 0.020 - 0.1% with respect to the composition.
2. The composition as claimed in claim 1, wherein the Thymus vulgaris extract has a weight percentage in the range of 0.020% - 0.1% with respect to the composition.
3. The composition as claimed in claim 1, wherein the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:1.25 -1:3.
4. The composition as claimed in claim 1, wherein the Angelica sinensis extract to the Thymus vulgaris extract w/w ratio is in the range of 1:0.25 -1:0.75.
5. The composition as claimed in claim 1, wherein the composition further comprises: (a) at least one carrier; (b) at least one diluent; and (c) at least one excipient.
6. A process for preparing the composition as claimed in any of the claims 1-4, said process comprising:

a) obtaining Angelica sinensis extract;
b) obtaining Thymus vulgaris extract; and
c) contacting the Angelica sinensis extract with the Thymus vulgaris extract,
to obtain the composition.
7. A process for preparing the composition as claimed in any one of the claims
1-5, said process comprising:
a) obtaining Angelica sinensis extract;
b) obtaining Thymus vulgaris extract;
c) obtaining at least one carrier, at least one diluent, and at least one excipient; and

d) contacting the Angelica sinensis extract, and the Thymus vulgaris extract, with the at least one carrier, the at least one diluent, and the at least one excipient, to obtain the composition.
8. The composition as claimed in claim 1, wherein the Angelica sinensis extract comprises lingustilides having a weight percentage in the range of 0.5% - 1.5% with respect to the extract.
9. The composition as claimed in claim 1, wherein the Thymus vulgaris extract comprises thymol having the weight percentage in the range of 0.06%) - 0.6%) with respect to the extract.
10. The composition as claimed in claim 1, wherein the composition inhibits prostaglandin PGF-2a production.